Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAST: Benralizumab Safety in Indian Severe Asthma
NCT05384938Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2021
- Primary completion
- Jul 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of benralizumab in eosinophilic asthma (EA), sponsored by AstraZeneca. Primary endpoints: Participants With Adverse Events (AEs), Serious AEs, and Treatment-emergent AEs at 24 weeks, Severity of AEs at 24 weeks and 1 more. Started Nov 2021; status: completed.
02
Drugs
benralizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on NCT05384938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05384938.